Zeto

Zeto operates at the intersection of medical devices, clinical software, and remote neurology services. Its core differentiation is an attempt to compress EEG setup and interpretation into a more deployable workflow: a wireless, gel-free, full-montage headset, cloud-based study management, synchronized video, remote access, and AI-supported seizure detection. The company states that setup can fall from more than 30 minutes to approximately five minutes, which is relevant for outpatient, emergency, and lower-resource settings. Zeto’s competitive reference point is therefore not only other digital-health software but also the incumbent hospital EEG workflow built around wired equipment, conductive gel, specialized technicians, and centralized neurologist access. Zeto’s position is clearer through its regulatory and product milestones: Zeto ONE is FDA-cleared, New Wave received FDA 510(k) clearance in April 2026, and NeuroPulse and NeuroNotis extend the platform into automated detection and reviewed reporting. The main strategic question is whether clinical customers adopt the integrated workflow broadly enough to offset the trust, validation, reimbursement, and implementation requirements typical of neurological diagnostics.

Zeto’s trajectory shows a progression from early clinical technology development to commercial scaling and platform expansion. The company was founded in 2014, raised seed capital in 2017 and 2018, and recorded a $7 million Series A in February 2020. Additional venture financing followed in 2022 and 2023, before a $31 million Series B led by Mindworks Global on Jan 8, 2025. Total funding is listed at $54.395 million across seven rounds, although one 2020 Series A entry lacks an amount and another financial input describes Series A as $7.3 million, creating a reconciliation concern. Product development has also broadened. Zeto ONE and the WR19 headset established the wireless dry-electrode foundation; NeuroPulse added AI-powered status epilepticus detection in April 2025; and New Wave extended the proposition toward outpatient and home EEG after FDA clearance in April 2026. NeuroNotis, introduced on Apr 16, 2026 with human review from Stratus technologists, suggests a shift toward report-generation and clinical workflow services rather than device sales alone. Neway Redia’s CFO appointment in March 2024 preceded the Series B and subsequent hospital partnerships, consistent with a company preparing its operating and commercial infrastructure for broader deployment.